IC
MIST icon

Ikarian Capital’s Milestone Pharmaceuticals MIST Stock Holding History

Ikarian Capital’s Portfolio MIST Stock Details MIST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-338,000
Closed -$3.11M – 99
2022
Q3 		$3.11M Buy
+338,000
New +$2.56M 0.62% 50

Other funds holding MIST

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
AFA
Alta Fundamental Advisers New York $265M AUM 98.61% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Ikarian Capital's MIST Position: Q1 2025 in Review

Ikarian Capital sold out of Milestone Pharmaceuticals (MIST) in Q1 2025, closing a stake of 466,030 shares — an estimated $1.1M sold.

Ikarian Capital first reported a position in MIST in Q3 2020 and held it in 18 quarters. The position peaked at $12.8M in Q3 2020. 43 funds tracked by Wall St. Rank hold MIST as of Q1 2025.

  • Ikarian Capital reported no remaining Milestone Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Ikarian Capital sold 466,030 Milestone Pharmaceuticals shares in Q1 2025, an estimated $1.1M.
  • Ikarian Capital first reported a position in Milestone Pharmaceuticals in Q3 2020 and held it in 18 quarters.
  • Ikarian Capital's Milestone Pharmaceuticals position peaked at $12.8M in Q3 2020.
  • 43 funds tracked by Wall St. Rank held Milestone Pharmaceuticals as of Q1 2025.

Based on Ikarian Capital's 13F filing for Q1 2025, filed 15 May 2025.